AR127450A1 - Moduladores del receptor ccr6 - Google Patents
Moduladores del receptor ccr6Info
- Publication number
- AR127450A1 AR127450A1 ARP220102895A ARP220102895A AR127450A1 AR 127450 A1 AR127450 A1 AR 127450A1 AR P220102895 A ARP220102895 A AR P220102895A AR P220102895 A ARP220102895 A AR P220102895A AR 127450 A1 AR127450 A1 AR 127450A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituent
- fluoroalkyl
- hydroxy
- hydroxyalkyl
- Prior art date
Links
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 title 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- -1 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-yl Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Chemical group 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010017079 CCR6 Receptors Proteins 0.000 abstract 1
- 102000004288 CCR6 Receptors Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (1), su síntesis y uso como moduladores del receptor CCR6 para la prevención o el tratamiento de, por ejemplo, enfermedades / trastornos inflamatorios / autoinmunes y el cáncer. Reivindicación 1: Un compuesto de la fórmula (1), en donde Q representa N, CH, o C-R, en donde R representa halógeno o alquilo C₁₋₃; R¹ representa alquilo C₁₋₃; R² representa hidrógeno; alquilo C₁₋₄; hidroxialquilo C₁₋₃; fluoroalquilo C₁₋₃; o cicloalquilo C₃₋₅; R³ᵃ representa halógeno; alquilo C₁₋₅; fluoroalquilo C₁₋₃; fluoroalcoxi C₁₋₃; cicloalquilo C₃₋₅; o 1-(fluoroalquilo C₁₋₃)-cicloalquilo C₃₋₅; R³ᵇ representa hidrógeno; o halógeno; R⁴ representa alquilo C₁₋₄ que es insustituido; mono sustituido, en donde el sustituyente se selecciona entre hidroxi o alquilamino C₁₋₃; o disustituido, en donde el primer sustituyente representa hidroxi, y el segundo sustituyente representa fluoroalquilo C₁; o -L-Cy, en donde -L- representa un enlace directo o -CH₂-; y Cy representa cicloalquilo C₃₋₇ que opcionalmente contiene un heteroátomo de anillo seleccionado entre nitrógeno u oxígeno; en donde Cy independientemente es insustituido; o monosustituido con hidroxi; oxo; alquilo C₁₋₄; -C(=O)RA, en donde RA representa alquilo C₁₋₃ o hidroxialquilo C₁₋₃; o alquil-carbonil-amino C₁₋₃; o disustituido, en donde el primer sustituyente representa oxo, y el segundo sustituyente representa alquilo C₁₋₃; o disustituido, en donde el primer sustituyente representa hidroxi y el segundo sustituyente representa alquilcarbonilo C₁₋₃; o Cy representa un sistema de anillo de hidrocarburo bicíclico puenteado de 5 a 8 miembros saturado, en donde Cy es independientemente monosustituido, en donde el sustituyente se selecciona entre hidroxialquilo C₁₋₃; o -C(=O)RB, en donde RB representa hidroxi; -NRN¹RN², en donde RN¹ y RN² representan independientemente hidrógeno o alquilo C₁₋₃; o RN¹ y RN² junto con el átomo de nitrógeno al que están unidos forman pirrolidinilo; o alcoxi C₁₋₃; o Cy representa un heteroarilo de 5 o 6 miembros que contiene uno o dos heteroátomos de anillo independientemente seleccionados entre nitrógeno u oxígeno; y R⁵ representa alquilo C₁₋₄; hidroxialquilo C₁₋₃; alcoxi C₁₋₃-alquilo C₁₋₃; cicloalquilo C₃₋₇; fluoroalquilo C₁₋₃; alquilcarbonilo C₁₋₃; o alquil-carbonil-amino C₁₋₃-alquilo C₁₋₃; o R⁴ y R⁵ junto con el anillo de triazolilo al que están unidos forman 5,6,7,8-tetrahidro-[1,2,4]triazolo[1,5-a]piridin-2-ilo o 6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-ilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2021079694 | 2021-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127450A1 true AR127450A1 (es) | 2024-01-24 |
Family
ID=84363087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102895A AR127450A1 (es) | 2021-10-26 | 2022-10-25 | Moduladores del receptor ccr6 |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR127450A1 (es) |
CA (1) | CA3235910A1 (es) |
TW (1) | TW202325278A (es) |
WO (1) | WO2023072924A1 (es) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3458635A (en) | 1966-08-08 | 1969-07-29 | Robins Co Inc A H | Compositions containing 3-di-substituted methylene pyrrolidines and methods of treating depression |
US3479370A (en) | 1966-08-08 | 1969-11-18 | Robins Co Inc A H | Esters of 1-substituted-3-disubstituted-pyrrolidinemethanols |
US3499002A (en) | 1968-06-20 | 1970-03-03 | Robins Co Inc A H | 1-carbamoyl-3-aroylpyrrolidines |
US3489769A (en) | 1968-06-20 | 1970-01-13 | Robins Co Inc A H | 1-substituted-3-aroyl-pyrrolidines |
US3651085A (en) | 1969-04-14 | 1972-03-21 | Robins Co Inc A H | 1-(omega-benzoylalkyl)-3-substituted pyrrolidines |
US3542807A (en) | 1969-04-14 | 1970-11-24 | Robins Co Inc A H | 1-(omega-benzoylalkyl)-3-substituted pyrrolidines |
US3694458A (en) | 1970-08-31 | 1972-09-26 | Robins Co Inc A H | 1-nitrosopyrrolidines |
US5278045A (en) | 1990-02-28 | 1994-01-11 | Du Pont Merck Pharmaceutical Company | Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function |
FR2775477B1 (fr) | 1998-02-27 | 2000-05-19 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique |
DE10144872A1 (de) | 2001-09-12 | 2003-03-27 | Bayer Cropscience Gmbh | Azetidinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
JP2009504768A (ja) | 2005-08-18 | 2009-02-05 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
WO2008103426A1 (en) | 2007-02-23 | 2008-08-28 | Theravance, Inc. | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists |
WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
CN103588697B (zh) | 2012-08-14 | 2017-09-15 | 中国科学院上海药物研究所 | 一类2,5‑二取代苯磺酰胺类化合物及其制备方法和用途 |
WO2014062658A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
WO2015057205A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
CN103800309A (zh) | 2012-11-15 | 2014-05-21 | 中国科学院上海药物研究所 | 金精三羧酸在制备靶向趋化因子受体的药物中的用途 |
ES2642074T3 (es) | 2013-09-04 | 2017-11-15 | Bristol-Myers Squibb Company | Compuestos útiles como inmunomoduladores |
CA2922607C (en) | 2013-09-06 | 2022-08-30 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
WO2015084842A1 (en) | 2013-12-02 | 2015-06-11 | Chemocentryx, Inc. | Ccr6 compounds |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
MA50424A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 |
RU2020128176A (ru) | 2018-01-26 | 2022-03-02 | Рапт Терапьютикс, Инк. | Модуляторы рецепторов хемокинов и их применение |
AU2019344107B2 (en) | 2018-09-21 | 2022-09-15 | Pfizer Inc. | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors |
KR20230005938A (ko) | 2020-04-30 | 2023-01-10 | 이도르시아 파마슈티컬스 리미티드 | Ccr6 수용체 조절인자로서의 아제티딘-3-일메탄올 유도체 |
-
2022
- 2022-10-25 WO PCT/EP2022/079766 patent/WO2023072924A1/en active Application Filing
- 2022-10-25 TW TW111140362A patent/TW202325278A/zh unknown
- 2022-10-25 CA CA3235910A patent/CA3235910A1/en active Pending
- 2022-10-25 AR ARP220102895A patent/AR127450A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202325278A (zh) | 2023-07-01 |
WO2023072924A1 (en) | 2023-05-04 |
CA3235910A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2743343C2 (ru) | Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм | |
JP5770842B2 (ja) | テトラヒドロ−ピリド−ピリミジン誘導体 | |
JP2021513555A (ja) | ピリミジン縮合環式化合物及びその製造方法、並びに使用 本出願は、出願日が2018年02月13日である中国特許出願cn201810144135.3の優先権、及び出願日が2018年06月29日である中国特許出願cn201810692211.4の優先権を主張する。本出願は上記中国出願の内容のすべてを引用する。 | |
TW202039483A (zh) | 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途 | |
ES2899665T3 (es) | Derivados de 2-(3-(1H-benzo[d]imidazol-1-il)propil)piperidin-3-ol y compuestos relacionados como inhibidores de PRS para el tratamiento, p. ej., del cáncer | |
US20030092712A1 (en) | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | |
CN102395589A (zh) | 稠合吡咯并吡啶衍生物 | |
EP2790705A1 (en) | Use of inhibitors of the activity or function of pi3k | |
EP3169681A1 (en) | Novel substituted pyrimidine compounds | |
KR20180052702A (ko) | Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체 | |
AR114564A1 (es) | DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE | |
US20230027198A1 (en) | Inhibitors of enl/af9 yeats | |
Weinberg et al. | Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds | |
AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
AR121676A1 (es) | DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1 | |
JP6454346B2 (ja) | 芳香族複素環式化合物及び医薬におけるその応用 | |
WO2018169700A1 (en) | Substituted heteroaryl compounds and methods of use | |
AR127450A1 (es) | Moduladores del receptor ccr6 | |
KR20170113627A (ko) | S100-저해제로서 사용가능한 이미다조[2,1-b]티아졸 및 5,6-다이하이드로이미다조[2,1-b]티아졸 유도체 | |
AR108327A1 (es) | Compuestos pirimidinona fusionados sustituidos | |
KR20210083287A (ko) | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 | |
US20230192703A1 (en) | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | |
US20220324862A1 (en) | Pyridopyrimidinone compounds | |
WO2022076831A2 (en) | Methods for treating cancer | |
TW202212331A (zh) | 作為egfr抑製劑之吲哚啉化合物及衍生物 |